Search Results for "Allergic Conjunctivitis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Allergic Conjunctivitis. Results 21 to 30 of 47 total matches.

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
. Drugs for allergic rhinitis and allergic conjunctivitis. Med Lett Drugs Ther 2021; 63:57. 4. FC Hampel ...
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4   doi:10.58347/tml.2023.1668c |  Show IntroductionHide Introduction

Omalizumab (Xolair) for Food Allergy

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
for allergic rhinitis and allergic conjunctivitis. Med Lett Drugs Ther 2021; 63:57. 3. Peanut allergen powder ...
Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been approved for use in conjunction with food allergen avoidance to reduce IgE-mediated food allergic reactions caused by accidental exposure in patients ≥1 year old. Omalizumab is the first drug to be approved in the US to reduce allergic reactions to more than one food. Palforzia, an oral peanut allergen powder, was approved in 2020 to mitigate allergic reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6   doi:10.58347/tml.2024.1699b |  Show IntroductionHide Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
and allergic conjunctivitis. Med Lett Drugs Ther 2025; 67:49. 2. Approximate WAC for 30 days’ treatment ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e55-7   doi:10.58347/tml.2025.1725b |  Show IntroductionHide Introduction

Loteprednol 0.25% (Eysuvis) for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
surgery, and seasonal allergic conjunctivitis. Pronunciation Key Loteprednol etabonate: loe” te pred ...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for short-term treatment (≤2 weeks) of dry eye disease. It is the first ocular corticosteroid to be approved for this indication. Other formulations of loteprednol are approved for treatment of steroid-responsive ocular inflammatory conditions, inflammation after ocular surgery, and seasonal allergic conjunctivitis.
Med Lett Drugs Ther. 2021 May 17;63(1624):75-7 |  Show IntroductionHide Introduction

Soft Contact Lenses

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990  (Issue 823)
wearers develop chronic allergic conjunctivitis with symptoms of eye irritation, discharge, and decreasing ...
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.
Med Lett Drugs Ther. 1990 Jul 27;32(823):69-70 |  Show IntroductionHide Introduction

Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
and allergic conjunctivitis. Med Lett Drugs Ther 2021; 63:57. 3. JS Mehta et al. Diagnosis, management ...
The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):70-2   doi:10.58347/tml.2023.1675d |  Show IntroductionHide Introduction

A Topical Prostaglandin for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Nov 08, 1996  (Issue 987)
outflow, but they may cause conjunctival hyperemia and, with chronic use, can cause allergic ...
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other drugs.
Med Lett Drugs Ther. 1996 Nov 8;38(987):100-1 |  Show IntroductionHide Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019  (Issue 1586)
macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis ...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 |  Show IntroductionHide Introduction

In Brief: Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025  (Issue 1730)
and Xolair for treatment of chronic spontaneous urticaria. FDA approval of Omlyclo for allergic asthma ...
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar to be approved in the US.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):95-6   doi:10.58347/tml.2025.1730f |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
. Hypersensitivity reactions including rash, allergic conjunctivitis, and anaphylaxis have been reported ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction